Dun-hua H. Zhou

P.r
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

A Teaching Case of Narrative Medicine Integrating Five-Education Innovation: An Exploration of the Full-Cycle Education Model at Sun Yat-sen University.

A Teaching Case of Narrative Medicine Integrating Five-Education Innovation: An Exploration of the Full-Cycle Education Model at Sun Yat-sen University.

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

Published: September 04, 2026

Acute megakaryoblastic leukemia with myeloid sarcoma among a pediatric patient harbouring RBM15::MRTFA: a case report and literature review.

Acute megakaryoblastic leukemia with myeloid sarcoma among a pediatric patient harbouring RBM15::MRTFA: a case report and literature review.

Journal: BMC pediatrics

Published: December 29, 2025

Poor Outcome of Pediatric Patients with Acute Lymphoblastic Leukemia Harboring Low P16 Deletion Ratio: A Post-Hoc Analysis from a Prospective Cohort.

Poor Outcome of Pediatric Patients with Acute Lymphoblastic Leukemia Harboring Low P16 Deletion Ratio: A Post-Hoc Analysis from a Prospective Cohort.

Journal: Blood and lymphatic cancer : targets and therapy

Published: December 28, 2025

Optimal minimal residual disease threshold in pediatric acute myeloid leukemia: A retrospective cohort study based on the TARGET database.

Optimal minimal residual disease threshold in pediatric acute myeloid leukemia: A retrospective cohort study based on the TARGET database.

Journal: PLoS medicine

Published: November 28, 2025

Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023.

Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023.

Journal: Cancer

Published: October 28, 2025

Early Identification of Differentiation Syndrome During ATRA and Arsenic Therapy in Pediatric NHR-APL: Insights From a 14-Year Multicenter Cohort.

Early Identification of Differentiation Syndrome During ATRA and Arsenic Therapy in Pediatric NHR-APL: Insights From a 14-Year Multicenter Cohort.

Journal: Pharmacoepidemiology and drug safety

Published: October 17, 2025

Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis.

Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis.

Journal: Hematology (Amsterdam, Netherlands)

Published: August 05, 2025

Prognostic scoring model incorporating clinical characteristics for pediatric hemophagocytic lymphohistiocytosis: a multicenter retrospective study.

Prognostic scoring model incorporating clinical characteristics for pediatric hemophagocytic lymphohistiocytosis: a multicenter retrospective study.

Journal: Annals of hematology

Published: July 18, 2025

Efficacy of Blinatumomab in the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia

Efficacy of Blinatumomab in the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia

Journal: Zhongguo shi yan xue ye xue za zhi

Published: July 04, 2025

Effect and mechanism of allopurinol in acute lymphoblastic leukemia maintenance therapy: Reducing hepatotoxicity and improving myelosuppression effect via thiopurine methyltransferase inhibition and increased DNA-thioguanine levels.

Effect and mechanism of allopurinol in acute lymphoblastic leukemia maintenance therapy: Reducing hepatotoxicity and improving myelosuppression effect via thiopurine methyltransferase inhibition and increased DNA-thioguanine levels.

Journal: Drug metabolism and disposition: the biological fate of chemicals

Published: April 24, 2025

Predictive Model of Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia on Event-Free Survival: Data Analysis Based on Trial AAML0531.

Predictive Model of Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia on Event-Free Survival: Data Analysis Based on Trial AAML0531.

Journal: Bioengineering (Basel, Switzerland)

Published: January 26, 2025

Corrigendum to "HIF-2α 1 inhibition disrupts leukemia stem cell metabolism and impairs vascular microenvironment to enhance chronic myeloid leukemia treatment" [Cancer lett. 597 (2024) 217060].

Corrigendum to "HIF-2α 1 inhibition disrupts leukemia stem cell metabolism and impairs vascular microenvironment to enhance chronic myeloid leukemia treatment" [Cancer lett. 597 (2024) 217060].

Journal: Cancer letters

Published: January 01, 2025

Showing 1-12 of 63

Last Updated: 09/26/2026